An old drug with a new future: Bendamustine in multiple myeloma

Massimo Gentile, Anna Grazia Recchia, Carla Mazzone, Ernesto Vigna, Massimo Martino, Lucio Morabito, Eugenio Lucia, Sabrina Bossio, Laura De Stefano, Teresa Granata, Angela Palummo, Fortunato Morabito

Research output: Contribution to journalArticle

Abstract

Introduction: Bendamustine is a unique bifunctional alkylating agent with promising activity in multiple myeloma (MM). It is currently licensed in Europe for use as frontline treatment with prednisolone for patients with MM who are unsuitable for transplantation and who are contraindicated for thalidomide and bortezomib therapy. Areas covered: Studies evaluating the safety and efficacy of bendamustine administered alone or in combination in both the upfront and relapse settings of MM patients, including those with renal insufficiency, were reviewed. The use of bendamustine as conditioning for autologous stem-cell transplantation and the possibility of stem-cell mobilization after bendamustine therapy are discussed. Expert opinion: Bendamustine seems to be efficacious either in monotherapy or in combination with other drugs in previously treated or untreated patients. This is due to its unique mechanism of action including its ability to activate apoptosis and inhibit mitotic checkpoints, making it potentially more effective than other alkylating agents. Moreover, it has an acceptable toxicity profile and is suitable for patients with renal impairment. Finally, this drug does not seem to compromise the possibility of achieving a stem-cell mobilization. Nonetheless, data from Phase III studies demonstrating its effectiveness in terms of overall survival are not yet available.

Original languageEnglish
Pages (from-to)2263-2280
Number of pages18
JournalExpert Opinion on Pharmacotherapy
Volume14
Issue number16
DOIs
Publication statusPublished - 2013

Keywords

  • ASCT
  • Bendamustine
  • Multiple myeloma
  • New drugs
  • Therapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Fingerprint Dive into the research topics of 'An old drug with a new future: Bendamustine in multiple myeloma'. Together they form a unique fingerprint.

  • Cite this

    Gentile, M., Recchia, A. G., Mazzone, C., Vigna, E., Martino, M., Morabito, L., Lucia, E., Bossio, S., De Stefano, L., Granata, T., Palummo, A., & Morabito, F. (2013). An old drug with a new future: Bendamustine in multiple myeloma. Expert Opinion on Pharmacotherapy, 14(16), 2263-2280. https://doi.org/10.1517/14656566.2013.837885